Matches in Wikidata for { <http://www.wikidata.org/entity/Q93151017> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q93151017 description "artículu científicu espublizáu en setiembre de 2019" @default.
- Q93151017 description "scientific article published on 13 September 2019" @default.
- Q93151017 description "wetenschappelijk artikel" @default.
- Q93151017 description "наукова стаття, опублікована 13 вересня 2019" @default.
- Q93151017 name "Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States" @default.
- Q93151017 name "Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States" @default.
- Q93151017 type Item @default.
- Q93151017 label "Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States" @default.
- Q93151017 label "Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States" @default.
- Q93151017 prefLabel "Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States" @default.
- Q93151017 prefLabel "Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States" @default.
- Q93151017 P1433 Q93151017-45AD0C57-9D22-4E2A-8473-9489E6FA861C @default.
- Q93151017 P1476 Q93151017-1B814025-0E26-4B49-8E88-CF1FEB6D102F @default.
- Q93151017 P2093 Q93151017-289C88CD-8F30-4968-B922-9001000A3862 @default.
- Q93151017 P2093 Q93151017-4942BC0F-FC91-4114-8393-D3D8ECFBAA32 @default.
- Q93151017 P2093 Q93151017-5CBEE662-BC5A-42EA-9063-4C2D6A1EA13F @default.
- Q93151017 P2093 Q93151017-90D90F1F-55C4-456C-82E5-A05269E53AB1 @default.
- Q93151017 P2093 Q93151017-9B33D313-8125-4512-9778-2E1E5F0493A8 @default.
- Q93151017 P2093 Q93151017-AAC6B23B-7573-40F0-A5AA-A3A78528846B @default.
- Q93151017 P2093 Q93151017-AF4726A8-C76D-4FA2-9FFD-A8C69BE45EB5 @default.
- Q93151017 P275 Q93151017-8CF6173E-2DC8-4376-B508-7C660D39A65A @default.
- Q93151017 P304 Q93151017-D72A99D7-2E7F-4572-A46E-E46BD99239CD @default.
- Q93151017 P31 Q93151017-557C6D8D-58A4-4D87-87BF-940C066A1E33 @default.
- Q93151017 P356 Q93151017-76FB9C14-DDF1-4D19-8EB0-2AEF191E8DD4 @default.
- Q93151017 P433 Q93151017-7FEB110A-EB8D-44FF-B419-3FD5BC4818C1 @default.
- Q93151017 P478 Q93151017-9C8F2027-3849-4BB4-B53C-403BD08B9867 @default.
- Q93151017 P577 Q93151017-18B91D2F-94AA-42F2-82C5-3AFC0DEFE831 @default.
- Q93151017 P6216 Q93151017-F42D9DF4-190C-46A6-8EDB-5321DF69A801 @default.
- Q93151017 P698 Q93151017-FA8F76E7-22EB-4460-A920-2659C445A3B6 @default.
- Q93151017 P921 Q93151017-119F5E49-AAB6-485A-A32C-EFC21EDE74C9 @default.
- Q93151017 P921 Q93151017-9D68B4C3-2DEC-418B-AE66-74BD25BCC042 @default.
- Q93151017 P921 Q93151017-EAADFB41-2923-41ED-A47A-F4000945ED90 @default.
- Q93151017 P356 03007995.2019.1660539 @default.
- Q93151017 P698 31491337 @default.
- Q93151017 P1433 Q5195063 @default.
- Q93151017 P1476 "Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States" @default.
- Q93151017 P2093 "Abhishek Kavati" @default.
- Q93151017 P2093 "Joseph Dang" @default.
- Q93151017 P2093 "Ming Yang" @default.
- Q93151017 P2093 "Patrick W Sullivan" @default.
- Q93151017 P2093 "Qianyi Li" @default.
- Q93151017 P2093 "S Pinar Bilir" @default.
- Q93151017 P2093 "Yamina Rajput" @default.
- Q93151017 P275 Q24082749 @default.
- Q93151017 P304 "23-32" @default.
- Q93151017 P31 Q13442814 @default.
- Q93151017 P356 "10.1080/03007995.2019.1660539" @default.
- Q93151017 P433 "1" @default.
- Q93151017 P478 "36" @default.
- Q93151017 P577 "2019-09-13T00:00:00Z" @default.
- Q93151017 P6216 Q50423863 @default.
- Q93151017 P698 "31491337" @default.
- Q93151017 P921 Q12301086 @default.
- Q93151017 P921 Q30 @default.
- Q93151017 P921 Q35869 @default.